3 documents found, page 1 of 1
Retraction notice to " IP1867B suppresses the Insulin-like Growth Factor 1 Rece...
Mihajluk, K.; Simms, C.; Reay, M.; A Madureira, Patricia; Howarth, A.; Murray, P.; Nasser, S.; Duckworth, C.A.; Pritchard, D.M.; Pilkington, G.J.This article has been retracted at the request of the Editor-in-Chief due to concerns regarding the legitimacy of images and data presented in the paper. Though a corrigendum (Can. Lett. Vol. 469, 2020, pages 524–535) was previously published to address some of these concerns, this corrigendum has also been found to contain errors and therefore cannot stand. Specific concerns are listed below.
Corrigendum to IP1867B suppresses the insulin-like growth factor 1 receptor (IG...
Mihajluk, K.; Simms, C.; Reay, M.; A Madureira, Patricia; Howarth, A.; Murray, P.; Nasser, S.; Duckworth, C. A.; Pritchard, D. M.; Pilkington, G. J.
IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating e...
Mihajluk, K.; Simms, C.; Reay, M.; Madureira, Patricia A; Howarth, A.; Murray, P.; Nasser, S.; Duckworth, C. A.; Pritchard, D. M.; Pilkington, G. J.High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and poor clinical prognosis. Clinical outcome is compounded by resistance to standard and novel therapeutics. We have evaluated reformulated aspirin (IP1867B) alone and in combination with conventional and novel anti-aHGG agents. We show that recent biopsy-derived aHGG models were highly resistant to conventional therapeut...